The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Adjuvant chemotherapy for early-stage breast cancer: Choice of regimen and associated hematologic toxicities in a metropolitan Australian hospital.
Katherine Mary Lovat
No relevant relationships to disclose
Hayden Christie
No relevant relationships to disclose
Ricky Che
No relevant relationships to disclose
Andrew Hill
No relevant relationships to disclose
Jasotha Sanmugarajah
No relevant relationships to disclose